Diabetes Liver Fibrosis Score to Detect Advanced Fibrosis in Diabetics with Nonalcoholic Fatty Liver Disease

Amandeep Singh; Rajat Garg; Rocio Lopez; Naim Alkhouri

doi:10.1016/j.cgh.2021.01.010

Diabetes Liver Fibrosis Score to Detect Advanced Fibrosis in Diabetics with Nonalcoholic Fatty Liver Disease

Clin Gastroenterol Hepatol. 2022 Mar;20(3):e624-e626. doi: 10.1016/j.cgh.2021.01.010. Epub 2021 Jan 9.

Authors

Amandeep Singh¹, Rajat Garg², Rocio Lopez³, Naim Alkhouri⁴

Affiliations

¹ Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: Singha4@ccf.org.
² Department of Hospital Medicine, Cleveland Clinic, Cleveland, Ohio.
³ Center for Populations Health Research, Cleveland Clinic, Cleveland, Ohio; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
⁴ Arizona Liver Institute, Scottsdale, Arizona.

PMID: 33434655
DOI: 10.1016/j.cgh.2021.01.010

Abstract

Type 2 diabetes (T2D) is a risk for advanced fibrosis (AF) in patients with nonalcoholic fatty liver disease (NAFLD). Recent data suggest that commonly used fibrosis scores (NAFLD fibrosis score [NFS], aspartate to alanine aminotransferase ratio [AST/ALT], AST to platelet ratio index, and Fibrosis-4) may have low sensitivity and negative predictive value to detect AF in patients with diabetes.^1,2 The aim of this study was to develop a simple noninvasive fibrosis score to detect AF in patients with diabetes and compare its performance with other fibrosis scores.

MeSH terms

Aspartate Aminotransferases
Biopsy
Diabetes Mellitus, Type 2* / complications
Fibrosis
Humans
Liver / diagnostic imaging
Liver / pathology
Liver Cirrhosis / complications
Liver Cirrhosis / diagnosis
Liver Cirrhosis / pathology
Non-alcoholic Fatty Liver Disease* / complications
Non-alcoholic Fatty Liver Disease* / diagnosis
Non-alcoholic Fatty Liver Disease* / pathology
Platelet Count

Substances

Aspartate Aminotransferases